Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
- The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
- Prophylactic treatment aims to prevent bleeds and allow people with haemophilia to achieve quality of life comparable to non-haemophilic individuals. Access to this is particularly restricted in developing countries, with the limited healthcare resources reserved for emergency situations and acute bleeds
- More than 940 people across 30 countries have already benefited from Roche’s donations since the start of the partnership in February 2019
Basel, 10 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has extended its commitment to the World Federation of Hemophilia (WFH) Humanitarian Aid Program until the end of 2028. Roche’s prophylactic treatment will be provided to the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with haemophilia A in locations where there is little to no access to treatment. The partnership, which was originally formed by Roche and the WFH in February 2019, marked the first time that patients in developing countries had received access to a prophylactic treatment. The donated treatment has since benefited more than 940 people across 30 countries.
“Our renewed commitment will allow us to continue to help people with haemophilia A most in need,” said Bill Anderson, CEO Roche Pharmaceuticals. “We are proud to be recognised by the WFH as a Visionary Contributor of the Program and are delighted to announce that our commitment to the WFH Humanitarian Aid Program has been extended until 2028.”
"Last year was a record year for the WFH Humanitarian Aid Program, which continues to make life-changing treatment accessible for those who need it most,” said Cesar Garrido, WFH President. "With Roche’s continued support, we will be able to continue the important work that the Humanitarian Aid Program does, giving people with bleeding disorders the hope of leading a normal life through prophylactic treatment."
Most people with bleeding disorders in developing countries have no access to diagnosis, treatment and care,1 which significantly affects their health, quality of life and life expectancy. Access to prophylactic treatment – the standard of care for haemophilia A to prevent bleeds in most of the developed world – is particularly restricted in developing countries, with the limited healthcare resources reserved for emergency situations and acute bleeds.2,3 In some developing countries, low dose prophylaxis has been developed as a solution to provide better care for those with haemophilia,4 although this does not provide the standard of care seen with higher dose prophylaxis regimens, considered the ‘gold standard’.2 People with severe haemophilia in these countries often do not survive to adulthood because they are unable to access the treatment they critically need.5 For those who do, life often entails severe disability, isolation and chronic pain.
The WFH Humanitarian Aid Program is a landmark initiative leading the effort to help address the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. So far, more than 22,000 people with haemophilia in over 112 countries have been treated with prophylactic and on-demand treatment thanks to the WFH Humanitarian Aid Program, with over 2,000 receiving prophylactic treatment.6
“Thanks to the WFH Humanitarian Aid Program, more people with haemophilia A are able to benefit from our prophylactic treatment, originated by Chugai; providing not only sustainable care to the individual, but ultimately benefiting their societies as a whole,” said Dr Osamu Okuda, Chugai’s President and Chief Executive Officer. “I am delighted that Chugai and Roche will continue to support the Program, so that we can ensure consistent access to our innovative and important prophylactic treatment through the WFH.”
About The WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.
About haemophilia A
Haemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly, leading to uncontrolled and often spontaneous bleeding. Haemophilia A affects around 900,000 people worldwide, approximately 35-39% of whom have a severe form of the disorder. People with haemophilia A either lack or do not have enough of a clotting protein called factor VIII. In a healthy person, when a bleed occurs, factor VIII brings together the clotting factors IXa and X, which is a critical step in the formation of a blood clot to help stop bleeding. Depending on the severity of their disorder, people with haemophilia A can bleed frequently, especially into their joints or muscles. These bleeds can present a significant health concern as they often cause pain and can lead to chronic swelling, deformity, reduced mobility, and long-term joint damage. A serious complication of treatment is the development of inhibitors to factor VIII replacement therapies. Inhibitors are antibodies developed by the body’s immune system that bind to and block the efficacy of replacement factor VIII, making it difficult, if not impossible, to obtain a level of factor VIII sufficient to control bleeding.
About Roche in haematology
Roche has been developing medicines for people with malignant and non-malignant blood diseases for over 20 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematological diseases. Our approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, and Hemlibra® (emicizumab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibodies, glofitamab and mosunetuzumab, targeting both CD20 and CD3, and cevostamab, targeting both FcRH5 and CD3; Tecentriq® (atezolizumab), a monoclonal antibody designed to bind with PD-L1; and crovalimab, an anti-C5 antibody engineered to optimise complement inhibition. Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
All trademarks used or mentioned in this release are protected by law.
 World Federation of Hemophilia. Achieving Global Impact – Strategic plan: 2021-2025 [Internet; cited May 2022]. Available from: https://wfh.org/wp-content/uploads/2021/12/WFH-Strategic-Plan-2021-2025.pdf.
 Poon MC and Lee A. Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations? Thrombosis Journal. 2016; 14:32.
 De Kleijn P. et al. Differences between developed and developing countries in paediatric care in haemophilia. Haemophilia. 2012;18:94-100.
 Sidharthan N and Sudevan R. Low Dose Prophylaxis in Hemophilia Care. Indian J Hematol Blood Transfus. 2020 Jan;36(1):16-25.
 Ghosh K and Ghosh K. Management of haemophilia in developing countries: challenges and options. Indian J Hematol Bloos Transfus. 2016 July-Sept; 32(3):347-355.
 World Federation of Hemophilia. Humanitarian Aid Program Impact Report [Internet; cited May 2022]. Available from: https://wfh.org/wp-content/uploads/2022/04/Humanitarian_Aid_2021_Impact_Report.pdf
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
|Dr. Hans Trees|
Phone: +41 61 687 41 47
Phone: +41 79 935 81 48
|Dr. Barbara von Schnurbein |
Phone: +41 61 687 89 67
Phone: +41 61 682 28 31
Phone: +41 79 327 54 74
Phone: +41 61 687 43 05
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FRO – Private acquisitions of Euronav shares in exchange for Frontline shares completed28.5.2022 12:01:09 CEST | Press release
FRO – Private acquisitions of Euronav shares in exchange for Frontline shares completed Frontline Ltd. (“Frontline” or the "Company") (NYSE: FRO – OSE: FRO) announces that it has agreed to acquire a total of 5,955,705 shares in Euronav N.V. (NYSE: EURN & Euronext: EURN) (“Euronav”) representing 2.95% of the outstanding shares in privately negotiated share exchange transactions with certain shareholders of Euronav N.V. where such shareholders of Euronav N.V. receive consideration shares in Frontline. Frontline will issue a total of 8,337,986 new shares as a result of these transactions, equivalent to an exchange ratio of 1.4. Frontline will be entitled to the declared USD 0,06 dividend to be paid by Euronav on the acquired shares on 8 June 2022. Settlement is expected to take place on or about 1 June 2022 by delivery of existing shares through a share lending arrangement with Frontline's main shareholder Hemen Holding Ltd. Following completion of the issue of the new Frontline shares, F
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma28.5.2022 00:58:29 CEST | Press release
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah treatment demonstrated – of patients who achieved a complete response, 85% were still in response at 12 months1 Kymriah can be administered in the outpatient setting, offering increased flexibility and potentially reducing the burden of therapy for patients and their care teams1,2 Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings1 Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. In accordance with the Accelerated Approval Program, continued approval for this indicati
ObsEva Announces Corporate Updates27.5.2022 22:01:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland– May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc. (JGB), which is structured to provide up to $135 million in borrowing capacity, available in nine tranches. The third tranche under the Securities Purchase Agreement was due to be funded on May 25, 2022. However, the tranche has not been funded as a result of ObsEva not meeting the funding condition that its volume-weighted average share price would not trade below $3.00 per share for five or more trading days during the 30 days prior to the funding date for the third tranche. Pursuant to the Am
CONDITIONS FOR PURCHASES OF CORPORATE BONDS27.5.2022 16:20:00 CEST | Press release
Bid procedure, 2022-06-01BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: HEMSO FASTIGHETS AB: XS2173253407, 2025-05-13 HEMSO FASTIGHETS AB: XS2269194572, 2023-12-07 VASAKRONAN AB: SE0010599183, 2023-12-20 VASAKRONAN AB: XS2391917205, 2025-03-28 ESSITY AB: XS2355204608, 2025-01-17 SCANIA CV AB: XS2297918349, 2023-11-11 SCANIA CV AB: XS2382157571, 2024-09-02 ELECTROLUX AB: XS2152294679, 2023-04-06 ELECTROLUX AB: XS1969611943, 2024-03-27 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2022-04-27Bid date2022-06-01Bid times10.30-11.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS2173253407: 30 mln SEK +/-30 mln SEK XS2269194572: 30 mln SEK +/-30 mln SEK SE0010599183: 30 mln SEK +/-30 mln SEK XS2391917205: 30 mln SEK +/-
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS27.5.2022 16:20:00 CEST | Press release
Bid procedure, 2022-06-03BondsSWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01 SWEDEN I/L BOND: 3114, SE0013748258, 2030-06-01 Bid date2022-06-03Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3113: 250 mln SEK +/-125 mln SEK 3114: 250 mln SEK +/-125 mln SEK Highest permitted bid volume (corresponding nominal amount)3113: 250 mln SEK per bid 3114: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-06-08Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-05-27 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be